Nucleic acid intercalating drug. The structure of 9-hydroxy-2,5,11- tetramethylpyrido[4,3-b]carbazolium (9-hydroxy-2,6- dimethylellipticinium) chloride monohydrate.
C19H19N2O.Cl. H2O, Mr = 344.6, triclinic, P1, alpha = 12.980 (1), b = 9.454 (2), c = 7.148 (1) A, alpha = 75.23 (2), beta = 99.73 (3), gamma = 91.83 (2) degree, V = 835.9 A3, Z = 2, Dm = 1.35 (2), Dx = 1.369 Mg m-3, lambda (Cu Ka) = 1.54178 A, mu = 2.11 mm-1, F(000) = 364, T 298 k, R 0.059 for 2767 observed reflections. Antitumour drug that displays one of the highest DNA affinities (4 x 10(6) M 1) among ellipticine derivatives. The structure analysis confirms the intercalation hypothesis. There is stacking of centrosymmetrically related parallel molecules along c, alternately spaced by 3.43 and 3.48 A. The crystal structure confirms the desolvation effect of the sixth nitrogen position.
Salahou
A
A
Laboratoire de Cristallographie et de Physique Cristalline (UA 144 CNRS), Université de Bordeaux I, France.
Courseille
C
C
Tsai
C C
CC
D000470:Alkaloids; D000970:Antineoplastic Agents; D004611:Ellipticines; D007364:Intercalating Agents; D008968:Molecular Conformation; D015394:Molecular Structure; D014961:X-Ray Diffraction
D000470:Alkaloids; D000970:Antineoplastic Agents; D004611:Ellipticines; D007364:Intercalating Agents; C053305:N(2),N(6)-dimethyl-9-hydroxyellipticinium